Inderal LA and Propranolol XL Are the Same Drug
Inderal LA (long-acting propranolol) and propranolol XL (extended-release propranolol) refer to the same type of sustained-release formulation of propranolol, though "Inderal LA" is a specific brand name while "propranolol XL" or "propranolol LA" are generic descriptors for extended-release propranolol formulations.
Understanding the Terminology
The confusion arises from pharmaceutical naming conventions:
- Inderal LA is the brand name for a specific long-acting (LA) formulation of propranolol manufactured originally by AstraZeneca 1
- Propranolol XL or Propranolol LA are generic terms describing any extended-release propranolol formulation
- Both terms describe sustained-release formulations designed for once-daily dosing, as opposed to immediate-release (IR) propranolol which requires multiple daily doses
Pharmacokinetic Profile
These extended-release formulations share key characteristics that distinguish them from immediate-release propranolol 2, 3:
- Prolonged terminal half-life of 8-11 hours (compared to 3-6 hours for immediate-release)
- Delayed and lower peak concentrations that reduce fluctuations in drug levels
- Sustained therapeutic effect throughout a 24-hour period with once-daily dosing
- Reduced bioavailability (30-50% less than conventional formulations due to increased first-pass hepatic metabolism) 3
The controlled-release mechanism allows gradual drug release, maintaining plasma concentrations at 24 hours that are higher than with conventional tablets 2.
Clinical Equivalence
Multiple guidelines reference these formulations interchangeably. The 2018 ACC/AHA hypertension guidelines list "Propranolol LA" with dosing of 80-160 mg once daily 4, 5, 6, 7, while the FDA-approved Inderal LA label describes the same dosing range and indications 1. Studies comparing Inderal LA to conventional propranolol demonstrate equivalent efficacy for:
- Hypertension control (blood pressure and heart rate) 1
- Angina management (exercise duration, ST-segment depression, anginal attack frequency) 1
- Cardiac arrhythmias (ventricular premature beats, heart rate control) 8
Research confirms that 160 mg of Inderal LA once daily produces comparable beta-blockade to 40 mg of conventional propranolol four times daily 9.
Important Clinical Distinctions
While the terms are essentially synonymous, be aware that:
- Different manufacturers may produce generic extended-release propranolol with slightly different release characteristics 9
- Bioavailability varies between formulations—some controlled-release preparations show better bioavailability than others 9
- Dose conversion is not 1:1 with immediate-release propranolol due to reduced bioavailability; typically requires 20-30% higher total daily dose for extended-release formulations
Practical Prescribing Guidance
When prescribing or dispensing:
- "Inderal LA" specifically refers to the brand-name product
- "Propranolol LA," "Propranolol XL," or "Propranolol ER" (extended-release) are generic equivalents
- Always specify once-daily dosing to distinguish from immediate-release formulations
- Standard dosing ranges from 80-160 mg once daily for most indications 4, 5, 6, 7, 1
The key clinical advantage of these formulations is improved compliance through once-daily dosing while maintaining sustained beta-blockade throughout the 24-hour period 2, 3.